X-Cell Medical: Putting Safety First
Executive Summary
Most medical device start-ups seeking to tap into the enormous drug-eluting stent market have focused on novel stent or stent platform design, on the theory that drug efficacy is a given. But X-Cell Medical is betting that they've come up with a better drug. And they're making their case by stressing the importance of safety.
You may also be interested in...
Industry Perspective - The Medtech Industry: A Look Back at 2006
The year 2006 may best be remembered for the handful of high-profile companies that struggled, but for all of the challenges that a few medical device companies faced individually, it's hard not to see 2006 as anything other than a robust year for the industry as a whole. It was also a year of impressive rebounds for many other device companies that had faced tough times.
TCT Highlights: Late Stent Thrombosis Controversy Continues
Late stent thrombosis (LST) concerns associated with drug-eluting stents (DES) dominated sessions at the 2006 Transcatheter Cardiovascular Therapeutics (TCT) annual conference, with additional long-term data presented on this topic. The general feeling expressed was one of relief that the expanded dataset presented at TCT showed the LST problem was not as bad as some had feared when the issue was discussed at the World Congress of Cardiology (WCC).
Building Billion-Dollar Businesses: An Interview with Robert Croce
Building a billion-dollar business in medical devices is rare enough; doing it twice is unheard of. In the course of a four-decade career, Bob Croce helped turn J&J into a giant in medical devices.